This product is an active protein and may elicit a biological response in vivo, handle with caution.
Centrifuge the vial prior to opening. Reconstitute in 10 mM Tris pH 8.0 to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4oC for 1 week or -20oC for future use. Repeated freeze thaw cycles will result in some loss of activity.
Androgen induced growth factor
Androgen-induced growth factor
Fibroblast growth factor 8
Fibroblast growth factor 8 (androgen induced)
Fibroblast growth factor 8 precursor
Heparin-binding growth factor 8
Stimulates growth of the cells in an autocrine manner. Mediates hormonal action on the growth of cancer cells.
Involvement in disease
Defects in FGF8 are the cause of Kallmann syndrome type 6 (KAL6) [MIM:612702]. Kallmann syndrome is a disorder that associates hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some patients other developmental anomalies can be present, which include renal agenesis, cleft lip and/or palate, selective tooth agenesis, and bimanual synkinesis. In some cases anosmia may be absent or inconspicuous. Defects in FGF8 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Belongs to the heparin-binding growth factors family.